Urokinase receptor mediates doxorubicin-induced vascular smooth muscle cell senescence via proteasomal degradation of TRF2

Journal of Vascular Research

Volumn 50, Issue 2, 2013, Pages 109-123

  Hodjat, Mahshid ^a   Haller, Hermann ^a   Dumler, Inna ^a   Kiyan, Yulia ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cell senescence; Doxorubicin; Telomeric repeat binding factor 2; Ubiquitin proteasome system; Urokinase receptor

Indexed keywords

DOXORUBICIN; TELOMERIC REPEAT BINDING FACTOR 2; UROKINASE RECEPTOR;

ARTICLE; BLOOD VESSEL INJURY; GENE SILENCING; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RNA INTERFERENCE; SENESCENCE; UBIQUITINATION; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL;

ANIMALS; CELL AGING; CELLS, CULTURED; DOXORUBICIN; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PRIMARY CELL CULTURE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RECOMBINANT FUSION PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TELOMERE; TELOMERIC REPEAT BINDING PROTEIN 2; TRANSFECTION; UBIQUITINATION; UMBILICAL ARTERIES;

EID: 84869227124     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000343000     Document Type: Article

References (37)

1. Ewer M, Ewer S: Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 2010; 7: 564-575.
2. Shi Y, Moon M, Dawood S, McManus B, Liu P: Mechanisms and management of doxorubicin cardiotoxicity. Herz 2011; 36: 296-305.
3. Murata T, Yamawaki H, Yoshimoto R, Hori M, Sato K, Ozaki H, Karaki H: Chronic effect of doxorubicin on vascular endothelium assessed by organ culture study. Br J Pharmacol 2001; 132: 1365-1373.
4. Yamaç D, Elmas C, Ozoul C, Keskil Z, Dursun A: Ultrastructural damage in vascular endothelium in rats treated with paclitaxel and doxorubicin. Ultrastruct Pathol 2006; 30: 103-110.
5. Yin D, Li C, Kao R, Ha T, Krishnaswamy G, Fitzgerald M, Stuart C: Angiopoietin-1 inhibits doxorubicin-induced human umbilical vein endothelial cell death by modulating fas expression and via the PI3K/Akt pathway. Endothelium 2004; 11: 247-252.
6. Keltai K, Cervenak L, Makó V, Doleschall Z, Zsáry A, Karádi I: Doxorubicin selectively suppresses mRNA expression and production of endothelin-1 in endothelial cells. Vascul Pharmacol 2010; 53: 209-214.
7. Owens GK, Kumar MS, Wamhoff BR: Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004; 84: 767-801.
8. Maejima Y, Adachi S, Ito H, Hirao K, Isobe M: Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage. Aging Cell 2008; 7: 125-136.
9. Ranek M, Wang X: Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy. Curr Hypertens Rep 2009; 11: 389-395.
10. Binder BR, Mihaly J, Prager GW: uPAR-uPAPAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007; 97: 336-342.
11. Kiyan Y, Limbourg A, Kiyan R, Tkachuk S, Limbourg F, Ovsianikov A, Chichkov B, Haller H, Dumler I: Urokinase receptor associates with myocardin to control vascular smooth muscle cells phenotype in vascular disease. Arterioscler Thromb Vasc Biol 2012; 32: 110-122.
12. Fallier-Becker P, Rupp J, Fingerle J, Betz E: Smooth Muscle Cells from Rabbit Aorta. Berlin, Springer, 1990.
13. Dimri G, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano E, Linskens M, Rubelj I, Pereira-Smith O, et al: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92: 9363-9367.
14. Debacq-Chainiaux F, Erusalimsky J, Campisi J, Toussaint O: Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 2009; 4: 1798-1806.
15. Caiolfa VR, Zamai M, Malengo G, Andolfo A, Madsen CD, Sutin J, Digman MA, Gratton E, Blasi F, Sidenius N: Monomer dimer dynamics and distribution of GPI-anchored uPAR are determined by cell surface protein assemblies. J Cell Biol 2007; 179: 1067-1082.
16. van Steensel B, Smogorzewska A, de Lange T: TRF2 protects human telomeres from endto-end fusions. Cell 1998; 92: 401-413.
17. Dahl JA, Collas P: A rapid micro chromatin immunoprecipitation assay (microchip). Nat Protoc 2008; 3: 1032-1045.
18. Zhang Y, Shi J, Li Y, Wei L: Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz) 2009; 57: 435-445.
19. Arola O, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki L: Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 2000; 60: 1789-1792.
20. Spallarossa P, Altieri P, Aloi C, Garibaldi S, Barisione C, Ghigliotti G, Fugazza G, Barsotti A, Brunelli C: Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2. Am J Physiol Heart Circ Physiol 2009; 297:H2169-H2181.
21. Kiyan J, Smith G, Haller H, Dumler I: Urokinase receptor-mediated phenotypic changes of vascular smooth muscle cells require involvement of membrane rafts. Biochem J 2009; 423: 343-351.
22. Kiyan Y, Kiyan R, Haller H, Dumler I: Urokinase-induced signaling in human vascular smooth muscle cells are mediated by PDGFR. EMBO J 2005; 24: 1787-1797.
23. Kunigal S, Kusch A, Tkachuk N, S. T, Jerke U, Haller H, Dumler I: Monocyte-expressed urokinase inhibits vascular smooth muscle cell growth by activating Stat1. Blood 2003; 102: 4377-4383.
24. Wang Y, Dang J, Wang H, Allgayer H, Murrell GAC, Boyd D: Identification of a novel nuclear factor-B sequence involved in expression of urokinase-type plasminogen activator receptor. Eur J Biochem 2000; 267: 3248-3254.
25. Lechel A, Satyanarayana A, Ju Z, Plentz R, Schaetzlein S, Rudolph C, Wilkens L, Wiemann S, Saretzki G, Malek N, Manns M, Buer J, Rudolph K: The cellular level of telomere dysfunction determines induction of senescence or apoptosis in vivo. EMBO Rep 2005; 6: 275-281.
26. Muñoz P, Blanco R, Blasco M: Role of the TRF2 telomeric protein in cancer and ageing. Cell Cycle 2006; 5: 718-721.
27. Ramadan K, Meerang M: Degradationlinked ubiquitin signal and proteasome are integral components of DNA double strand break repair: new perspectives for anti-cancer therapy. FEBS Lett 2011; 585: 2868-2875.
28. Fujita K, Horikawa I, Mondal A, Jenkins L, Appella E, Vojtesek B, Bourdon J, Lane D, Harris C: Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. Nat Cell Biol 2010; 12: 1205-1212.
29. De Boeck G, Forsyth R, Praet M, Hogendoorn P: Telomere-associated proteins: cross-talk between telomere maintenance and telomere-lengthening mechanisms. J Pathol 2009; 217: 327-344.
30. Smith H, Marshall C: Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010; 11: 23-36.
31. Blasi F, Carmeliet P: uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-943.
32. Nowicki T, Zhao H, Darzynkiewicz Z, Moscatello A, Shin E, Schantz S, Tiwari R, Geliebter J: Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells. Cell Cycle 2011; 10: 100-107.
33. Yoshida C, Niiya K, Niiya M, Shibakura M, Asaumi N, Tanimoto M: Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells. Blood Coagul Fibrinolysis 2007; 18: 425-433.
34. Niiya M, Niiya K, Kiguchi T, Shibakura M, Asaumi N, Shinagawa K, Ishimaru F, Kiura K, Ikeda K, Ueoka H, Tanimoto M: Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells. Cancer Chemother Pharmacol 2003; 52: 391-398.
35. Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J: Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008; 6: 2853-2868.
36. Vucic D, Dixit V, Wertz I: Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol 2011; 12: 439-452.
37. Bao W, Strömblad S: Integrin-v-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen. J Cell Biol 2004; 167: 745-756.